[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352858-105":59,"doc-detail-352858-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","bcrabl1-induced-enhancer-reprogramming-uncovers-hypersensitivity-of-phb-all-cells-to-enhancer-targeting-drugs","BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs","","Cancer progression is driven by genomic lesions that reshape malignancy-promoting transcriptional programs, often via transcription factors acting through enhancers. For Philadelphia chromosome-positive (Ph+) B-lineage acute lymphoblastic leukemia (Ph+B-ALL), driven by BCR::ABL1, enhancer reprogramming defines the transcriptional state and yields enhancer signatures distinguishing it from other leukemias. Mechanistically, BCR::ABL1 activates enhancers through kinase activity and kinase-dependent STAT5, ETV5, and MYC, creating hypersensitivity to enhancer inhibition and improving enhancer-targeted drug efficacy alongside BCR::ABL1 kinase inhibitors, especially in IKZF1PLUS patients.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bcrabl1-induced-enhancer-reprogramming-uncovers-hypersensitivity-of-phb-all-cells-to-enhancer-targeting-drugs/352858/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bcrabl1-induced-enhancer-reprogramming-uncovers-hypersensitivity-of-phb-all-cells-to-enhancer-targeting-drugs/352858.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does enhancer reprogramming play in Ph+B-ALL?","Question",{"text":113,"@type":114},"Enhancer reprogramming defines the transcriptional state in Ph+B-ALL, and enhancer signatures differentiate it from other leukemias.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does BCR::ABL1 induce enhancer activation?",{"text":118,"@type":114},"BCR::ABL1 activates enhancers through its kinase activity and via kinase-dependent activation of STAT5, ETV5, and MYC.",{"name":120,"@type":111,"acceptedAnswer":121},"Why are Ph+B-ALL cells sensitive to enhancer-targeting drugs?",{"text":122,"@type":114},"Genes induced by BCR::ABL1 become hypersensitive to enhancer inhibition, making Ph+B-ALL cells hypersensitive to enhancer-targeting drugs.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352858,1790186119,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Advanced Science    \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nBCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs  \nHan Leng Ng1   Trudy Lee Glaser1  Jintao Zhu1  Mark E. Robinson2  Kadriye N. Cosgun2  Valeriya Malysheva3, 4, 5  Ozgen Deniz6  Nicholas T. Crump1, 7  Kaiyue Helian1  Andrew J. Innes1  Li Sun1  George John1  Haibin Zhou8  Atsunori Kaneshige8  Longchuan Bai8  Shaomeng Wang8 Mikhail Spivakov3, 4  Markus Müschen2  Niklas Feldhahn1   \nRichard Burt1  \n1 Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK  2 Center of Molecular and Cellular Oncology, Yale University, New Haven, Connecticut, USA  3MRC London Institute of Medical Sciences, London, UK  4 Institute of Clinical Sciences, Faculty of Medicine, Imperial College, London, UK  5VIB Center for Molecular Neurology, University of Antwerp, Belgium, VIB Center for AI and Computational Biology, Leuven, Belgium  6 Barts Cancer Institute, Queen Mary University of London, London, UK  7The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, London, UK  8 Department of Internal Medicine, Medical School, University of Michigan, Ann Arbor, Michigan, USA  \nCorrespondence: Niklas Feldhahn ([n.feldhahn@imperial.ac.uk](n.feldhahn@imperial.ac.uk))  \nReceived: 5 September 2025  Revised: 15 February 2026  Accepted: 15 February 2026  \nKeywords: BCR::ABL1 | CBP/P300 inhibitors | enhancer reprogramming | leukemia | Ph+B-ALL  \nABSTRACT  \nCancer is driven by genomic lesions and malignancy-promoting transcriptional programs. In blood cancers, both are often interconnected as lesions frequently affect transcription factor (TF)-encoding genes. TFs largely function through enhancers, and enhancer deregulation is linked to cancer initiation and progression. Consequently, enhancer-targeting drugs are in trials for several advanced hematologic cancers. However, for cancers not driven by TF-related lesions, it is less clear how their transcriptional programs are established; if oncogenesis involves enhancer-deregulation, and if they are sensitive to therapeutic enhancer-targeting. Here, we explore this for Philadelphia chromosome-positive (Ph+) B-lineage leukemia (B-ALL), the most common B-ALL in adults with a historically poor prognosis. Ph+B-ALL is driven by BCR::ABL1, a kinase without TF-related function. We report that malignant transformation and transcriptional reprogramming by BCR::ABL1 is indeed defined by enhancer reprogramming and that enhancer signatures differentiate Ph+B-ALL from other leukemias. Mechanistically, we show that BCR::ABL1 itself induces enhancer activation, through its kinase activity and via kinase-dependent activation of STAT5, ETV5, and MYC. Consequently, BCR::ABL1-induced genes are hypersensitive to enhancer inhibition, and Ph+B-ALL cells are hypersensitive to enhancer-targeting drugs. Enhancer-targeting further improves the efficacy of BCR::ABL1 kinase inhibitors used for Ph+B-ALL therapy, especially in cells from IKZF1PLUS patients that most frequently relapse from current treatment, suggesting enhancer-targeting as a potential promising addition to current therapy.  \n\n| Han Leng Ng and Trudy Lee Glaser contributed equally to this work.\u003Cbr>[Correction added on 10 March 2026 after online publication: author name Markus Müschen is corrected in this version.]\u003Cbr>|\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Author(s). Advanced Science published by Wiley-VCH GmbH |\n\nAdvanced Science, 2026; 13:e17231 1 of 22  \n[https://doi.org/10.1002/advs.202517231](https://doi.org/10.1002/advs.202517231)  \n1  Introduction  \nAcute-lymphoblastic leukemia (ALL) is the most common cancer, the second most common cause","cbCaiqmBMg4JhjHj","https://ap.wps.com/l/cbCaiqmBMg4JhjHj","pdf",6949939,22,"English","# Introduction\n## Background: enhancers in cancer\n## Enhancer-targeting therapy and trials\n## Ph+B-ALL and BCR::ABL1 treatment context","[{\"question\":\"What role does enhancer reprogramming play in Ph+B-ALL?\",\"answer\":\"Enhancer reprogramming defines the transcriptional state in Ph+B-ALL, and enhancer signatures differentiate it from other leukemias.\"},{\"question\":\"How does BCR::ABL1 induce enhancer activation?\",\"answer\":\"BCR::ABL1 activates enhancers through its kinase activity and via kinase-dependent activation of STAT5, ETV5, and MYC.\"},{\"question\":\"Why are Ph+B-ALL cells sensitive to enhancer-targeting drugs?\",\"answer\":\"Genes induced by BCR::ABL1 become hypersensitive to enhancer inhibition, making Ph+B-ALL cells hypersensitive to enhancer-targeting drugs.\"}]","BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs | PDF",1790101764,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/221ed50cbf5924e48f8581c60f269010.webp",983,1283,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9928ed82d48507c95d830b15b68a3c2e.webp",982,1281,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7e45091717fbd6bf950cd047d6c94ad.webp",981,1280,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ab257fea1bb28e81a6da64d70b5c443.webp",980,1279]